Fingolimod Orion
Sphingosine 1-phosphate receptor modulator for relapsing-remitting multiple sclerosis
Quick Facts About Fingolimod Orion
Key Takeaways About Fingolimod Orion
- First-dose cardiac monitoring is mandatory: All patients must be observed for at least 6 hours after their first dose due to the risk of bradycardia and AV conduction delays
- Reduces MS relapse rate by approximately 50%: Clinical trials (FREEDOMS, TRANSFORMS) demonstrated significant reduction in annualised relapse rate compared to placebo and interferon beta-1a
- Lymphopenia is expected, not a side effect to fear: The mechanism of action intentionally reduces circulating lymphocytes; counts typically recover within 1-2 months after stopping
- Contraindicated in pregnancy: Women of childbearing potential must use effective contraception during treatment and for 2 months after discontinuation
- Requires comprehensive pre-treatment screening: Cardiac evaluation (ECG), ophthalmologic examination, liver function tests, full blood count, varicella-zoster antibody status, and current medications must all be assessed before starting
What Is Fingolimod Orion and What Is It Used For?
Fingolimod Orion is a disease-modifying therapy (DMT) used to treat relapsing-remitting multiple sclerosis (RRMS) in adults and in children aged 10 years and older with highly active disease. It contains the active substance fingolimod, a sphingosine 1-phosphate (S1P) receptor modulator that reduces the frequency and severity of MS relapses and slows disability progression.
Multiple sclerosis (MS) is a chronic autoimmune disease in which the body's immune system mistakenly attacks the protective myelin sheath surrounding nerve fibres in the brain and spinal cord. This demyelination disrupts the transmission of nerve signals, leading to a wide range of neurological symptoms including vision problems, muscle weakness, numbness, fatigue, and cognitive difficulties. In relapsing-remitting MS, the most common form of the disease, patients experience periods of new or worsening symptoms (relapses) followed by partial or complete recovery (remissions).
Fingolimod was the first oral disease-modifying therapy approved for MS, representing a significant advancement over earlier injectable treatments. It was originally developed under the brand name Gilenya by Novartis and received approval from the European Medicines Agency (EMA) and the US Food and Drug Administration (FDA) in 2010-2011. Fingolimod Orion is a generic formulation manufactured by Orion Corporation, containing the same active substance at the same strength (0.5 mg) in hard capsule form.
The mechanism of action of fingolimod is distinct from other MS therapies. After oral administration, fingolimod is phosphorylated by sphingosine kinase to form the active metabolite fingolimod-phosphate. This metabolite binds to sphingosine 1-phosphate (S1P) receptors on lymphocytes, causing internalisation and functional antagonism of these receptors. The result is that lymphocytes, particularly the naive and central memory T cells that drive MS pathology, become sequestered in lymph nodes and cannot migrate to the central nervous system to cause inflammatory damage. Importantly, effector memory T cells, which are important for immune surveillance against infections, are relatively spared.
Beyond its immunomodulatory effects, research suggests that fingolimod may also exert direct neuroprotective effects within the central nervous system. S1P receptors are expressed on neurons, astrocytes, and oligodendrocytes, and fingolimod-phosphate can cross the blood-brain barrier. Preclinical studies have demonstrated that it promotes oligodendrocyte survival, enhances remyelination, and reduces astrogliosis. These potential neuroprotective properties are an active area of ongoing research and may contribute to the clinical benefits observed beyond relapse reduction.
Indications
Fingolimod Orion is indicated as a single disease-modifying therapy in highly active relapsing-remitting multiple sclerosis for the following patient groups:
- Adults and children aged 10 years and older with highly active disease despite a full and adequate course of treatment with at least one disease-modifying therapy
- Adults with rapidly evolving severe relapsing-remitting MS, defined by 2 or more disabling relapses in one year and 1 or more gadolinium-enhancing lesions on brain MRI, or a significant increase in T2 lesion load compared to a previous recent MRI
Fingolimod Orion should only be prescribed and supervised by physicians experienced in the management of multiple sclerosis. Treatment initiation requires access to appropriate cardiac monitoring facilities. The decision to prescribe fingolimod should take into account the individual patient's disease activity, overall health status, and the risk-benefit profile compared to other available MS treatments.
What Should You Know Before Taking Fingolimod Orion?
Before starting Fingolimod Orion, your doctor must perform a comprehensive set of pre-treatment assessments including cardiac evaluation, eye examination, liver function tests, full blood count, and varicella-zoster virus antibody status. Several serious conditions and medications contraindicate its use, particularly recent cardiovascular events and concomitant use of certain heart rate-lowering drugs.
Contraindications
Fingolimod Orion must not be used in the following situations:
- Known immunodeficiency syndrome – patients with severely compromised immune function are at unacceptable risk of serious infections
- Increased risk of opportunistic infections – including patients receiving immunosuppressive therapies or those with severe active infections until the infection is resolved
- Severe active infections or active chronic infections such as hepatitis or tuberculosis
- Known active malignancies – except basal cell carcinoma of the skin
- Severe liver impairment (Child-Pugh class C)
- Cardiovascular conditions in the preceding 6 months: myocardial infarction, unstable angina, stroke, transient ischaemic attack, decompensated heart failure requiring hospitalisation, or Class III/IV heart failure (NYHA classification)
- Severe cardiac arrhythmias requiring treatment with Class Ia or Class III antiarrhythmic medicinal products
- Second-degree Mobitz type II or higher AV block, sick sinus syndrome, or sino-atrial heart block (unless the patient has a functioning pacemaker)
- Baseline QTc interval ≥ 500 ms
- Pregnancy and women of childbearing potential not using effective contraception
- Hypersensitivity to fingolimod or any of the excipients
Warnings and Precautions
Several important warnings and precautions apply to the use of Fingolimod Orion. Patients and prescribers should be aware of the following risks and monitoring requirements:
Bradycardia and atrioventricular conduction delays: Initiation of fingolimod treatment results in a transient decrease in heart rate and may also be associated with atrioventricular conduction delays, including isolated reports of complete (third-degree) AV block. After the first dose, the decline in heart rate starts within one hour and is generally maximal within 6 hours. Heart rate usually returns to baseline within 1 month of continuous treatment. Because of this effect, all patients must undergo first-dose monitoring with continuous ECG for at least 6 hours.
Infections: Fingolimod reduces the peripheral lymphocyte count to approximately 20-30% of baseline values. This pharmacological effect increases susceptibility to infections, including potentially serious and life-threatening opportunistic infections. Cases of fatal infections caused by herpes simplex virus (disseminated herpes), varicella-zoster virus, progressive multifocal leukoencephalopathy (PML) caused by JC virus, and cryptococcal infections have been reported. Patients should be advised to report symptoms of infection promptly, and treatment should not be initiated in patients with severe active infections.
Macular oedema: Fingolimod is associated with an increased risk of macular oedema, typically occurring within the first 3-4 months of therapy. An ophthalmologic evaluation is recommended 3-4 months after treatment initiation. Patients with a history of uveitis or diabetes mellitus are at increased risk and should have regular ophthalmologic assessments throughout treatment.
Hepatic effects: Elevations of liver transaminases, primarily alanine aminotransferase (ALT), have been reported in patients treated with fingolimod. Liver function tests should be obtained before treatment initiation and monitored periodically during treatment. If ALT exceeds 5 times the upper limit of normal, more frequent monitoring should be implemented, including serum bilirubin and alkaline phosphatase measurements.
Posterior reversible encephalopathy syndrome (PRES): Rare cases of PRES have been reported with fingolimod at the recommended dose. Symptoms may include sudden onset of severe headache, altered mental status, visual disturbances, and seizures. If PRES is suspected, fingolimod should be discontinued immediately.
Cases of PML, a rare and serious brain infection caused by the JC virus, have been reported with fingolimod. PML usually leads to death or severe disability. There is no known effective treatment for PML. Risk factors include duration of therapy and prior immunosuppressive treatment. Patients should be monitored for new or worsening neurological symptoms, and MRI should be performed if PML is suspected. Fingolimod must be permanently discontinued if PML is confirmed.
Pregnancy and Breastfeeding
Fingolimod Orion is classified as contraindicated during pregnancy. Animal studies have demonstrated reproductive toxicity, including teratogenicity (fetal malformations) at doses comparable to those used clinically. Human data from post-marketing surveillance have confirmed an approximately 2-fold increased risk of major congenital malformations when fingolimod is taken during the first trimester of pregnancy. The most commonly reported malformations involve the heart (ventricular and atrial septal defects) and the kidneys.
Women of childbearing potential must be informed about the serious risk to the fetus and must have a negative pregnancy test before starting treatment. Effective contraception must be used during treatment and for at least 2 months after stopping fingolimod, because the substance takes approximately 2 months to be eliminated from the body. If a woman becomes pregnant during treatment, fingolimod must be stopped immediately and the patient should be referred for specialist prenatal monitoring.
Fingolimod is excreted in the milk of treated animals. Because of the potential for serious adverse reactions in nursing infants, women should not breastfeed during treatment with Fingolimod Orion.
How Does Fingolimod Orion Interact with Other Drugs?
Fingolimod Orion has clinically significant interactions with heart rate-lowering medicines (beta-blockers, calcium channel blockers, digoxin), other immunosuppressive therapies, live vaccines, and certain CYP450 enzyme inhibitors. These interactions can increase the risk of bradycardia, immunosuppression, or altered drug levels.
Drug interactions with fingolimod are a critical consideration because they can significantly amplify the cardiac, immunological, and hepatic risks associated with the medicine. The prescribing physician must conduct a thorough review of all current medications before initiating treatment. The following sections describe the most important interactions, categorised by clinical severity.
Major Interactions
The following drug interactions are considered major and may require avoidance, dose adjustment, or enhanced monitoring:
| Interacting Drug/Class | Effect | Clinical Action |
|---|---|---|
| Beta-blockers (atenolol, metoprolol, propranolol) | Additive bradycardic effect; increased risk of symptomatic bradycardia and AV block | Generally avoid. If co-administration is required, consult a cardiologist and perform extended first-dose monitoring (overnight) |
| Calcium channel blockers (diltiazem, verapamil) | Additive heart rate-lowering effect; increased risk of serious bradycardia | Avoid heart rate-lowering calcium channel blockers. If essential, extended cardiac monitoring required at treatment initiation |
| Class Ia antiarrhythmics (quinidine, procainamide, disopyramide) | Risk of torsade de pointes ventricular tachycardia in conjunction with fingolimod-induced bradycardia | Contraindicated. Do not co-administer |
| Class III antiarrhythmics (amiodarone, sotalol, dronedarone) | Risk of torsade de pointes ventricular tachycardia in conjunction with fingolimod-induced bradycardia | Contraindicated. Do not co-administer |
| Other immunosuppressants (azathioprine, ciclosporin, mitoxantrone) | Additive immunosuppressive effect; increased risk of serious infections | Avoid. Allow adequate washout period when switching from other immunosuppressive DMTs |
| Live attenuated vaccines (MMR, varicella, yellow fever, BCG) | Risk of uncontrolled infection from live vaccine; impaired vaccine response | Avoid live vaccines during treatment and for 2 months after stopping. Complete all necessary vaccinations at least 1 month before starting fingolimod |
Minor Interactions
The following interactions are considered minor or moderate and may require awareness but generally do not prevent co-administration:
| Interacting Drug/Class | Effect | Clinical Action |
|---|---|---|
| Ketoconazole (potent CYP4F2 inhibitor) | Increases fingolimod exposure by approximately 1.7-fold due to CYP4F2 inhibition | Use with caution. Monitor for increased adverse effects |
| Carbamazepine (CYP3A4 inducer) | May reduce fingolimod exposure by approximately 40% | Be aware of potential reduced efficacy. Clinical significance uncertain but exercise caution |
| Inactivated vaccines (influenza, pneumococcal, COVID-19) | Reduced immune response to vaccination; potentially lower antibody titres | Vaccination may be less effective. Consider checking antibody levels post-vaccination. Inactivated vaccines can be given during treatment |
| Digoxin | No pharmacokinetic interaction, but additive heart rate-lowering effect possible | Extended first-dose monitoring may be advisable |
When switching to fingolimod from other disease-modifying therapies, the half-life and mode of action of the previous therapy must be considered to avoid unintended additive immunosuppression. For example, after stopping natalizumab, a washout period of at least 6 weeks is generally recommended. After interferon beta or glatiramer acetate, treatment can usually begin immediately if blood counts are normal. Always follow the specific switching guidelines provided by your treating neurologist.
What Is the Correct Dosage of Fingolimod Orion?
The recommended dose of Fingolimod Orion is one 0.5 mg capsule taken orally once daily for adults. For children aged 10 years and older, the dose depends on body weight: 0.25 mg once daily for patients weighing ≤40 kg, and 0.5 mg once daily for those weighing >40 kg. First-dose monitoring is required for all patients.
Adults
Adult Dosage (18 years and older)
Standard dose: 0.5 mg (one capsule) taken orally once daily, with or without food.
The capsule should be swallowed whole with water. It should not be opened, crushed, or chewed. Fingolimod can be taken at any time of day, but it is recommended to take it at the same time each day to maintain consistent blood levels. There is no need to adjust the dose based on kidney function, even in patients with severe renal impairment, as renal excretion is a minor elimination pathway. In patients with mild to moderate hepatic impairment (Child-Pugh class A or B), no dose adjustment is necessary, but careful monitoring is recommended.
Children
Paediatric Dosage (10 years and older)
Body weight ≤40 kg: 0.25 mg once daily
Body weight >40 kg: 0.5 mg once daily
Fingolimod Orion is indicated in children aged 10 years and older with highly active relapsing-remitting MS. The paediatric indication was approved based on the PARADIGMS trial, which demonstrated a 82% relative reduction in annualised relapse rate compared to interferon beta-1a in paediatric patients. Paediatric patients should be managed by a specialist experienced in paediatric MS.
Elderly
Elderly Patients (65 years and older)
Clinical experience with fingolimod in patients aged 65 years and over is limited. No specific dose adjustment is recommended, but elderly patients should be monitored more carefully for adverse effects given the potential for increased comorbidities and polypharmacy. Particular attention should be paid to cardiac monitoring at treatment initiation and to the increased susceptibility to infections that may be present in older individuals.
First-Dose Monitoring Protocol
All patients initiating Fingolimod Orion must undergo first-dose observation. This monitoring protocol is a critical safety requirement and must not be omitted:
- Pre-dose: Obtain a baseline ECG and blood pressure measurement before the first dose
- Administration: The first dose should be taken in a clinical setting with access to resuscitation equipment
- Monitoring period (minimum 6 hours): Continuous ECG monitoring, with hourly measurement of pulse rate and blood pressure
- Post-monitoring ECG: Obtain a 12-lead ECG at the end of the 6-hour monitoring period
- Extended monitoring: If the heart rate at hour 6 is the lowest value recorded, extend monitoring for at least 2 additional hours and until heart rate increases. If second-degree or higher AV block, new-onset or clinically relevant bradycardia, or QTc ≥500 ms occurs, initiate appropriate management and continue monitoring until resolved
Missed Dose
If a dose is missed during the first 2 weeks of treatment, contact your doctor because re-initiation of first-dose monitoring may be required. After the first 2 weeks of treatment, if one dose is missed, take the next dose at the usual scheduled time. Do not take a double dose to make up for a forgotten dose. If treatment is interrupted for more than 14 consecutive days at any point during therapy, first-dose monitoring procedures must be repeated when restarting treatment. This is because the cardiac effects of fingolimod recur upon re-exposure after a prolonged gap in treatment.
Overdose
In the event of overdose, the most important clinical concern is bradycardia. In healthy volunteers, a single dose of 5 mg (10 times the recommended dose) resulted in a heart rate decrease of approximately 12 beats per minute. Overdose should be managed with continuous cardiac monitoring, symptomatic treatment, and supportive care. Fingolimod cannot be removed by dialysis or plasma exchange. If overdose is suspected, contact a poison control centre or seek immediate medical attention.
What Are the Side Effects of Fingolimod Orion?
The most common side effects of Fingolimod Orion include headache, liver enzyme elevation, diarrhoea, cough, influenza, sinusitis, and lymphopenia (reduced lymphocyte count). Serious but less common side effects include bradycardia at first dose, macular oedema, increased risk of infections (including PML), and skin cancers. The following frequency grid summarises known adverse effects.
Like all medicines, Fingolimod Orion can cause side effects, although not everybody experiences them. The side effects listed below are based on the pooled safety data from clinical trials involving over 3,000 patients treated with fingolimod 0.5 mg, as well as extensive post-marketing surveillance. It is important to understand that many of these side effects are related to the pharmacological action of the drug and are therefore predictable and manageable with appropriate monitoring.
The overall safety profile of fingolimod has been well characterised over more than a decade of clinical use worldwide. Most common adverse effects are mild to moderate in severity and do not require treatment discontinuation. However, some serious adverse reactions require prompt medical attention and may necessitate stopping the medication. Patients should be educated about the warning signs of serious complications, particularly infections, cardiac events, and visual disturbances.
Very Common (affects more than 1 in 10 patients)
- Influenza viral infections
- Headache
- Cough
- Lymphopenia (reduced lymphocyte count – expected pharmacological effect)
- Liver transaminase elevation (ALT/AST increase)
Common (affects 1 to 10 in 100 patients)
- Herpes viral infections (oral herpes, herpes zoster)
- Bronchitis, sinusitis
- Tinea infections (fungal skin infections)
- Diarrhoea, nausea
- Back pain
- Dizziness
- Migraine
- Blurred vision
- Bradycardia (slowed heart rate, especially at first dose)
- Atrioventricular block (first-degree)
- Hypertension
- Dyspnoea (shortness of breath)
- Eczema, alopecia (hair loss), pruritus (itching)
- Blood triglyceride increase
- Leucopenia (reduced white blood cell count)
- Fatigue, asthenia (weakness)
- Weight loss
Uncommon (affects 1 to 10 in 1,000 patients)
- Pneumonia
- Macular oedema (swelling of the central part of the retina)
- Depressed mood, depression
- Neutropenia (reduced neutrophil count)
- Second-degree AV block (Mobitz type I / Wenckebach)
- Thrombocytopenia (reduced platelet count)
Rare (affects fewer than 1 in 1,000 patients)
- Progressive multifocal leukoencephalopathy (PML)
- Cryptococcal infections (meningitis)
- Posterior reversible encephalopathy syndrome (PRES)
- Lymphoma
- Basal cell carcinoma and squamous cell carcinoma of the skin
- Kaposi sarcoma
- Haemophagocytic syndrome
- Peripheral arterial occlusive disease
Contact your doctor or seek emergency medical care immediately if you experience: signs of serious infection (high fever, severe headache with stiff neck, visual loss, confusion, seizures); symptoms of macular oedema (blurred vision, distorted central vision, shadows); chest pain, irregular heartbeat, or severe dizziness; unexplained skin changes or new skin lesions; symptoms of liver problems (yellowing of skin/eyes, dark urine, severe abdominal pain); or unusual neurological symptoms (progressive weakness, speech difficulties, personality changes).
How Should You Store Fingolimod Orion?
Store Fingolimod Orion below 25°C in the original packaging to protect from moisture. Keep out of the reach and sight of children. Do not use after the expiry date stated on the carton and blister pack.
Proper storage of Fingolimod Orion is essential to ensure the medication remains effective and safe throughout its shelf life. The capsules should be stored at room temperature, not exceeding 25°C (77°F). They should be kept in their original blister packaging until the time of use to protect them from moisture exposure, which can degrade the active substance.
Do not store Fingolimod Orion in the bathroom or near a sink, as the humidity in these environments may affect the stability of the capsules. Do not freeze the medication. If you are travelling with your medication, keep it in a cool, dry place and avoid prolonged exposure to direct sunlight or extreme heat, such as in a car glove compartment during summer months.
Check the expiry date on the carton and blister packaging before each use. Do not use the capsules if the expiry date has passed. Any unused medicine or waste material should be disposed of in accordance with local requirements. Do not dispose of medicines via wastewater or household waste. Ask your pharmacist how to dispose of medicines you no longer use. These measures will help protect the environment.
What Does Fingolimod Orion Contain?
Each Fingolimod Orion hard capsule contains 0.5 mg of fingolimod (as fingolimod hydrochloride) as the active substance. The capsule also contains excipients including mannitol, hydroxypropylcellulose, hydroxypropylbetadex, magnesium stearate, and the capsule shell components gelatin, titanium dioxide, and iron oxide yellow.
The active substance in Fingolimod Orion is fingolimod hydrochloride, equivalent to 0.5 mg of fingolimod base. Fingolimod is a structural analogue of the endogenous lipid mediator sphingosine 1-phosphate and was originally derived from myriocin, a metabolite of the fungus Isaria sinclairii, which has been used in traditional Chinese medicine.
The excipients (inactive ingredients) in the capsule contents serve specific pharmaceutical purposes. Mannitol is used as a filler and bulking agent. Hydroxypropylcellulose functions as a binder and disintegrant, aiding in the dissolution of the capsule contents. Hydroxypropylbetadex (a cyclodextrin derivative) serves as a solubiliser to enhance the bioavailability of fingolimod. Magnesium stearate is a lubricant that prevents the capsule contents from sticking to manufacturing equipment.
The capsule shell is composed of gelatin (the structural component), titanium dioxide (E171, a white colouring agent), and iron oxide yellow (E172, which gives the capsule its characteristic colour). Patients with known allergies to any of these excipients should inform their prescriber before starting treatment.
Fingolimod Orion is a generic medicinal product that has been shown to be bioequivalent to the reference product Gilenya. This means it contains the same active substance, in the same dose, and achieves the same blood levels as the original branded product. Bioequivalence was demonstrated through pharmacokinetic studies conducted according to EMA guidelines, confirming that Fingolimod Orion and the reference product can be expected to have the same clinical effects and safety profile.
Frequently Asked Questions About Fingolimod Orion
Fingolimod Orion is used to treat relapsing-remitting multiple sclerosis (RRMS) in adults and in children aged 10 years and older with highly active disease. It is classified as a disease-modifying therapy (DMT) that reduces the frequency of MS relapses and slows disability progression by preventing immune cells from migrating to the central nervous system. It is prescribed by specialist neurologists and is typically considered for patients who have had inadequate response to at least one other MS therapy, or for those with rapidly evolving severe disease.
First-dose monitoring is required because fingolimod causes a temporary decrease in heart rate (bradycardia) and can slow electrical conduction through the heart (AV block) when the first dose is taken. This effect begins within one hour and is usually most pronounced within 6 hours. All patients must be monitored continuously with ECG and have hourly blood pressure and pulse measurements for at least 6 hours. Most patients tolerate the first dose well, and the heart rate effect diminishes with subsequent daily doses. If first-dose monitoring results are abnormal, extended monitoring is performed until the findings resolve.
The most common side effects include headache, liver enzyme elevations, influenza, cough, diarrhoea, sinusitis, back pain, and lymphopenia (reduced lymphocyte count, which is expected from the drug's mechanism). Bradycardia (slowed heart rate) is common at the first dose but usually resolves. Less common but important side effects include macular oedema (eye swelling), herpes infections, and skin cancers. Most common side effects are manageable and do not require stopping treatment. Your doctor will monitor you regularly for liver function, blood counts, and other potential complications.
No. Fingolimod Orion is strictly contraindicated during pregnancy because it can cause birth defects, particularly heart and kidney malformations. Women of childbearing potential must use effective contraception during treatment and for at least 2 months after stopping, as the drug takes approximately 2 months to be fully eliminated from the body. A negative pregnancy test is required before starting. Breastfeeding is also not recommended as fingolimod passes into breast milk. If you are planning a pregnancy, discuss this with your neurologist well in advance so treatment can be safely discontinued with appropriate planning.
Fingolimod has been extensively studied in large clinical trials. The FREEDOMS trial showed a 54% reduction in annualised relapse rate compared to placebo over 2 years, and the TRANSFORMS trial showed a 52% reduction compared to interferon beta-1a (intramuscular) over 1 year. It also significantly reduced MRI lesion activity and slowed brain atrophy. In paediatric patients (PARADIGMS trial), fingolimod demonstrated an 82% reduction in relapse rate compared to interferon beta-1a. The clinical benefits have been confirmed in extensive real-world studies with over 300,000 patient-years of exposure worldwide.
When fingolimod is discontinued, lymphocyte counts typically return to normal within 1 to 2 months, though it may take longer in some patients. There is a recognised risk of severe disease reactivation (rebound) after stopping fingolimod, with some patients experiencing a marked increase in MS relapse activity and new MRI lesions within a few months of discontinuation. This rebound phenomenon appears to be more common than the disease activity experienced before starting treatment. For this reason, stopping fingolimod should be carefully planned with your neurologist, with close clinical and MRI monitoring during the transition period, and timely initiation of an alternative disease-modifying therapy when appropriate.
All information is based on international medical guidelines and peer-reviewed research: the EMA Summary of Product Characteristics (SmPC) for fingolimod, FDA prescribing information, the FREEDOMS and TRANSFORMS pivotal clinical trials, the PARADIGMS paediatric trial, the AAN Practice Guidelines for Disease-Modifying Therapies in MS (2018), the ECTRIMS-EAN guidelines on pharmacological treatment of MS (2024), and Cochrane systematic reviews. All medical claims have evidence level 1A, the highest quality of evidence based on systematic reviews of randomised controlled trials.
References and Medical Sources
This article is based on the following peer-reviewed sources and international medical guidelines. All medical claims reflect Evidence Level 1A where applicable.
- European Medicines Agency (EMA). Summary of Product Characteristics: Fingolimod. Last updated 2024. Available from: www.ema.europa.eu
- Kappos L, Radue EW, O'Connor P, et al. A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis (FREEDOMS). N Engl J Med. 2010;362(5):387-401. doi:10.1056/NEJMoa0909494
- Cohen JA, Barkhof F, Comi G, et al. Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis (TRANSFORMS). N Engl J Med. 2010;362(5):402-415. doi:10.1056/NEJMoa0907839
- Chitnis T, Arnold DL, Banwell B, et al. Trial of fingolimod versus interferon beta-1a in pediatric multiple sclerosis (PARADIGMS). N Engl J Med. 2018;379(11):1017-1027. doi:10.1056/NEJMoa1800149
- Rae-Grant A, Day GS, Marrie RA, et al. Practice guideline recommendations summary: Disease-modifying therapies for adults with multiple sclerosis. Neurology. 2018;90(17):777-788. doi:10.1212/WNL.0000000000005347
- Montalban X, Gold R, Thompson AJ, et al. ECTRIMS/EAN guideline on the pharmacological treatment of people with multiple sclerosis. Mult Scler. 2018;24(2):96-120. doi:10.1177/1352458517751049
- La Mantia L, Tramacere I, Firwana B, et al. Fingolimod for relapsing-remitting multiple sclerosis. Cochrane Database Syst Rev. 2016;(4):CD009371. doi:10.1002/14651858.CD009371.pub2
- US Food and Drug Administration (FDA). Gilenya (fingolimod) prescribing information. Reference ID: 5067547. Available from: www.fda.gov
- World Health Organization (WHO). WHO Model List of Essential Medicines, 23rd List, 2023. Geneva: World Health Organization; 2023.
- Berger JR, Cree BA, Greenberg B, et al. Progressive multifocal leukoencephalopathy after fingolimod treatment. Neurology. 2018;90(20):e1815-e1821. doi:10.1212/WNL.0000000000005529
About the Medical Editorial Team
This article has been written and reviewed by the iMedic Medical Editorial Team, comprising licensed specialist physicians with expertise in neurology, clinical pharmacology, and immunology. Our editorial process follows the GRADE evidence framework, and all content is reviewed according to international guidelines from the WHO, EMA, FDA, and leading medical societies.
iMedic Medical Editorial Team – Specialists in neurology and clinical pharmacology with documented academic background and clinical experience in multiple sclerosis management.
iMedic Medical Review Board – Independent panel of board-certified physicians who review all content according to international guidelines. No pharmaceutical company sponsorship or conflicts of interest.
Evidence standard: Level 1A – Based on systematic reviews of randomised controlled trials (FREEDOMS, TRANSFORMS, PARADIGMS) and international treatment guidelines (AAN, ECTRIMS-EAN, EMA SmPC, FDA label).
Last medical review:
Next scheduled review: